Roche boosts cancer approvals in Europe, pushing for a bigger slice of the I/O pie

Roche is stacking up approvals for its flagship checkpoint inhibitor in the lucrative field of lung cancer. On Friday, the Swiss drugmaker revealed that the European Commission had endorsed the use of Tecentriq in combination with chemotherapy as the first line of defense in certain patients with advanced non-squamous non-small cell lung cancer (NSCLC).